Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.

Read at benzinga.com

← All stock news